The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Meiji Plans Japan-Bound Generic Projection in India to Seek Cost Competitiveness
June 1, 2016
- Meiji Seika Pharma Pins High Hopes on Schizophrenia Drug Sycrest
June 1, 2016
- Daiichi Sankyo Ceases Development of Patritumab for NSCLC
June 1, 2016
- Oncolys Concludes Option Agreement with US CRO for HIV Treatment Censavudine
June 1, 2016
- Takeda Consumer Healthcare Unit Aims for 100 Billion Yen Sales after Spin-Off
May 31, 2016
- Terumo Debuts Cell-Based Heart Failure Therapy HeartSheet
May 31, 2016
- Takeda’s Myeloma Drug Hopeful Ninlaro Rebuffed by CHMP
May 31, 2016
- Takeda Gets CHMP’s Positive Opinion for New Adcetris Indication
May 31, 2016
- Mylan Japan Labor Union, Management Reach Settlement; All 14 Members to Leave on May 31
May 30, 2016
- Ethical Drug Sales Up 6.1% in March: Crecon Report
May 30, 2016
- Application Filing Expected in FY2018 for Cancer Peptide Vaccine Originating from Kurume Univ.
May 30, 2016
- Kyorin to Exclusively Market MSD’s Desloratadine in Japan
May 27, 2016
- Astellas Grants Thunderbolt Pharma Rights for BAFF/APRIL Dual Antagonist Program
May 26, 2016
- Eisai Rolls Out AMPA Receptor Antagonist Fycompa
May 26, 2016
- AZ Launches Tagrisso for Treatment of NSCLC
May 26, 2016
- Shionogi’s Naldemedine Delivers Positive Results in Global PIII
May 25, 2016
- Hyperparathyroidism Drug Etelcalcetide Meets Primary Endpoint in Japan PIII: Ono
May 25, 2016
- Toyama Chemical Files Ozex for Mycoplasma Pneumoniae at Request of Academic Societies
May 25, 2016
- Bardoxolone Methyl Improves Renal Function in Japan PII: Kyowa Kirin
May 24, 2016
- PCSK9 Inhibitor Alirocumab Lowers LDL-C in Japanese Diabetes Patients: PIII Sub-Analysis
May 24, 2016
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…